简体中文
EnglishWebsite review
This review may include AI-generated content and is not individually verified. Domain, certificate and other facts come from the observed data on this page.
What is BiologicsCorp?
BiologicsCorp is a contract research company focused on custom protein and antibody production. Its services are aimed at research labs and biotech teams that need recombinant proteins, antibodies, or engineered cell lines but prefer to outsource the work rather than build the capability in-house. According to its site, the offering spans four main areas:
- Protein production — recombinant protein expression using mammalian, bacterial, yeast, and insect systems, plus fermentation and high-throughput options.
- Custom antibody services — monoclonal and polyclonal antibody production, antibody pairing, labeling, and sequencing (hybridoma and de novo).
- Cell line services — cell lines for research or production, gene knockout cell lines, and stable cell line construction.
- Analysis and engineering — protein interaction analysis (GST pull-down, co-immunoprecipitation, bio-layer interferometry) and antibody engineering such as scFv, Fab, chimeric, and recombinant antibody expression.
Who it suits
The typical user is a scientist who has a gene or antibody sequence and wants a finished reagent or expression construct back. For example, a lab studying a signaling pathway might send a target sequence for recombinant expression in mammalian cells, then order a matching polyclonal antibody for validation. A group developing a therapeutic candidate might instead need stable cell line construction and chimeric or humanized antibody formats.
The trade-off is standard for outsourcing: you gain access to multiple expression platforms and antibody engineering expertise without maintaining them internally, but you give up day-to-day control over timelines and must depend on the provider's communication. The site also offers free bioinformatics tools (codon usage tables, GC content and codon calculators, a rare codon analyzer), which are useful for early sequence optimization before committing to a production order.
Next step
If you have a specific project in mind, start by deciding which expression system fits your protein — mammalian for complex folding and glycosylation, bacterial for simple, high-yield targets — then use the bioinformatics tools to check your sequence. From there, request a quote with your sequence and desired quantity so the provider can confirm feasibility and turnaround.
How do I choose between mammalian and bacterial expression systems for my recombinant protein?
The short answer: choose bacterial expression when you need a simple, inexpensive, fast route to a non-glycosylated protein that folds well in the cytoplasm, and choose mammalian expression when correct folding, disulfide bonding, glycosylation or secretion matters for your downstream use. BiologicsCorp offers both routes as services, so the decision is mainly about your protein's biology rather than the vendor's capability.
Quick comparison
| Factor | Bacterial (E. coli) | Mammalian |
|---|---|---|
| Speed and cost | Usually faster and cheaper | Slower, more resource-intensive |
| Glycosylation | None | Human-like glycan patterns |
| Complex disulfide bonds | Often problematic | Generally well handled |
| Folding of eukaryotic domains | Frequently misfolds | Closer to native |
| Typical use | Antigens, tags, enzymes, structural studies | Antibodies, receptors, therapeutic candidates |
| Scale-up | Straightforward fermentation | Transient or stable cell line development |
BiologicsCorp lists bacterial and mammalian systems alongside yeast and insect options, plus fermentation and high-throughput services, so you can pick the system that fits the target rather than adapting the target to one platform.
A practical decision path
- Check the sequence. If the protein has no glycosylation sites and no complex disulfide network, bacterial expression is the sensible first attempt. BiologicsCorp's free bioinformatics tools, including a codon usage calculator and rare codon analyzer, help flag expression problems before you commit.
- Ask what the protein is for. For immunization or a binding assay, a bacterial antigen is often adequate. For a functional receptor or an antibody destined for cell-based work, mammalian expression is usually the safer choice.
- Consider the format. BiologicsCorp's recombinant antibody services cover IgG, IgE, IgD and fragments such as scFv, Fab and VHH, and antibodies are a classic case where mammalian expression pays off because assembly and glycosylation affect behavior.
- Plan for failure. Run the cheap bacterial route first for a non-glycosylated target, and keep mammalian expression as the fallback if the protein aggregates or is inactive.
Example scenario
Suppose you are producing a cytokine for a cell-based assay. Bacterial expression may give you insoluble protein requiring refolding, which BiologicsCorp discusses in its resources; a mammalian transient system is more likely to yield soluble, active protein directly. If instead you need an enzyme for a biochemical assay and it has no glycans, bacterial expression will usually get you there sooner and at lower cost.
Next step
Send BiologicsCorp the target sequence, intended application and required quantity through its quick quote form, and ask which system it recommends and why. If you want a second opinion on platform fit, compare notes with established providers such as Thermo Fisher Scientific or GenScript before committing to a route.
What is the process for custom monoclonal antibody production from start to finish?
Custom monoclonal antibody production is typically a staged service: sequence design, expression, screening, scale-up and purification. BiologicsCorp lists monoclonal antibody production alongside supporting steps such as antibody sequencing, recombinant antibody expression, hybridoma sequencing and antibody pairing, so a project can be handled as one linked workflow rather than isolated jobs.
Typical start-to-finish workflow
- Define the target and starting material. You may begin from a hybridoma line, an existing antibody sequence, or a gene sequence. If only the protein is known, sequencing services (hybridoma or de novo) establish the variable regions first.
- Sequence and engineer the antibody. The variable regions are cloned into an expression construct, often as IgG, or reformatted into fragments such as scFv, Fab or chimeric formats.
- Choose an expression system. Mammalian expression is the usual route for full-length antibodies because it supports correct folding and glycosylation; bacterial systems suit fragments or simpler proteins and are faster and cheaper. Yeast and insect systems sit between these options.
- Transfect and express. Transient expression gives material quickly for testing. Stable cell line generation takes longer but produces a consistent supply for larger or repeat batches.
- Screen and select clones. Binding, specificity and expression level are checked, and the best clones are carried forward.
- Scale up and purify. Fermentation or larger culture volumes are followed by purification and quality checks such as purity and activity assays.
- Validate and deliver. The final antibody is characterised for binding affinity, and interaction analysis methods such as bio-layer interferometry can measure binding kinetics.
Choosing between routes
| Starting point | Typical first step | Main trade-off |
|---|---|---|
| Hybridoma | Hybridoma sequencing, then recombinant expression | Fast if the hybridoma is stable, but sequence recovery can fail |
| Known sequence | Direct gene synthesis and cloning | Most predictable, but requires accurate sequence data |
| Protein antigen only | Immunisation or library screening | Slower and less certain, since lead selection is empirical |
Practical next step
Write down three things before requesting a quote: your starting material, whether you need a full-length IgG or a fragment, and how much antibody you need over time. A one-off small batch points to transient expression; a long-running project points to stable cell line development. If you are unsure which format fits your assay, ask for a comparison of full-length IgG against Fab or scFv before committing, since format affects tissue penetration, clearance and detection options.
Can BiologicsCorp develop a stable cell line for my specific research or production needs?
Yes. Stable cell line construction is one of BiologicsCorp's listed service areas, alongside recombinant protein and antibody production. The site distinguishes between cell lines for research and cell lines for production, which is a useful split because the two goals have different priorities.
What that distinction means in practice
- A research cell line usually prioritizes getting a reliable, well-characterized tool quickly, so you can run assays and generate reproducible data.
- A production cell line usually prioritizes long-term stability, consistent expression over many passages, and scalability toward larger batches.
If you are unsure which you need, the deciding question is whether the cells are an experimental tool or part of a product you intend to make repeatedly.
How to move forward
Prepare a short brief before requesting a quote: your target protein or antibody format, the host species and cell type you want, whether you need transient or stable expression, the expression level you need, and any selection markers or culture constraints. The site's listed capabilities include mammalian and bacterial expression systems, recombinant antibody formats such as IgG, Fab, scFv, and VHH, and supporting analysis like bio-layer interferometry for binding measurements, so you can often combine cell line work with downstream characterization.
A practical first step is to use the site's quick quote route with that brief and ask specifically how they assess clone stability and expression consistency, since those are the questions that determine whether a line still works for you six months later.
What services does BiologicsCorp offer for antibody engineering and modification?
BiologicsCorp offers antibody engineering and modification as a set of related services rather than a single package, according to its site navigation and service descriptions on BiologicsCorp. The engineering work sits alongside its antibody production and sequencing services, which matters if you need a modified antibody built from a known sequence.
Antibody engineering services listed
- scFv construction — building single-chain variable fragments.
- Fab antibody — producing Fab fragments.
- Chimeric antibody — combining antibody domains from different sources.
- Recombinant antibody expression — expressing formats such as IgG, IgE, and IgD, plus scFv, diabody/discFv, Fab, sdAb, and VHH, and Fc fusion proteins.
How this fits with other services
The engineering offerings are supported by upstream and downstream capabilities: hybridoma sequencing and de novo antibody sequencing for determining sequences, custom monoclonal and polyclonal antibody production, antibody pairing and labeling, and cell line services for research or production. Protein interaction analysis (GST pull-down, co-immunoprecipitation, bio-layer interferometry) is also listed, which is useful when you need binding data on an engineered construct rather than just the material.
Practical decision criteria
- If you have an existing hybridoma but want a humanized or chimeric version, start from sequencing, then move to chimeric or scFv/Fab construction and recombinant expression.
- If you need a smaller format for tissue penetration or fusion to a payload, scFv, Fab, sdAb, or VHH are the relevant routes.
- If you need a full-length effector-competent antibody, IgG expression plus Fc fusion options are the closer fit.
- If you already know the sequence, engineering and expression can begin without the discovery steps.
A useful next step is to check whether the specific format you need appears in the service list and to request a quote with your sequence, desired format, and required quantity, since turnaround and feasibility depend heavily on those three details.
How can I get a quote and what is the typical turnaround time for BiologicsCorp's services?
Get a quote by using BiologicsCorp's Quick Quote path on BiologicsCorp, then describe your project so the team can scope it. Turnaround time is not stated on the page, so treat any timeline as project-specific and confirm it in the quote.
What to send with a quote request
- Service type: protein production, custom antibody production, antibody engineering, cell line services or interaction analysis.
- Expression system: mammalian, bacterial, yeast or insect, if you already know it.
- Molecule details: protein or antibody format, such as IgG, Fab, scFv, VHH or Fc fusion.
- Scale and purity: how much material you need and what downstream use it is for.
- Sequence or construct information: share only through the company's official process, not in a public form.
How to judge the turnaround answer
Ask for a stage-by-stage schedule rather than one total figure: gene synthesis or construct prep, expression, purification, QC and shipping. A quote that separates these stages is easier to compare with another provider and easier to plan around.
For example, a lab needing a small amount of a standard recombinant protein for a pilot assay has a different timeline from one needing a stable cell line plus antibody production. The first may be quoted as a shorter defined project; the second usually depends on cell line development and clone selection, which are inherently longer.
Practical next step
Submit the Quick Quote form with your construct and assay context, and ask three direct questions: what is the estimated delivery date, what milestones trigger payment, and what happens if expression or purification underperforms. That turns the quote into a usable project plan rather than a price alone.
GoDaddy
Zoho Mail
User reviews (0)